Sinovac Biotech Ltd

NAS:SVAHealthcarenasdaq_composite

$6.47−0.31%LiveIn session · ≈ AED 23.76 · Market cap $464.94M · Next earnings Thu 17 Dec

Ratio	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	Current · undated	YoY
Gross margin	86.8%	94.5%	54.1%	59.5%	61.1%	67.9%	—	—
Operating margin	42.2%	90.6%	−31.2%	−122.0%	−139.9%	−75.5%	−75.5%	+0.0 pts
Net margin	21.6%	43.7%	7.6%	−22.3%	25.2%	−15.5%	−15.5%	+0.0 pts
EBITDA margin	43.4%	91.1%	12.3%	−1.3%	−109.4%	−48.6%	—	—
Return on equity	14.8%	90.8%	1.3%	−1.1%	1.1%	−1.3%	−0.9%	+0.4 pts
Return on assets	5.8%	50.6%	0.8%	−0.7%	0.7%	−0.7%	−0.7%	+0.0 pts
Return on capital employed	17.7%	122.4%	−3.6%	−4.4%	−4.6%	−4.1%	—	—
Debt / equity	0.2×	0.0×	0.0×	0.0×	0.0×	0.1×	0.1×	−30.6%
Debt / assets	7.2%	0.9%	0.5%	2.2%	3.0%	5.9%	—	—
Interest coverage	148.4×	6,189.4×	−368.7×	−241.9×	−89.7×	−29.7×	—	—
Current ratio	2.3×	6.2×	11.1×	10.3×	7.3×	4.6×	4.6×	+0.0%
Quick ratio	2.1×	6.0×	10.9×	10.2×	7.3×	4.5×	—	—
Cash ratio	1.5×	4.8×	3.9×	1.1×	0.2×	0.8×	0.8×	+0.0%
Asset turnover	0.3×	1.2×	0.1×	0.0×	0.0×	0.0×	—	—
Inventory turnover	0.6×	2.9×	3.8×	1.3×	1.5×	1.3×	—	—
Receivables turnover	2.0×	20.3×	2.4×	1.0×	1.2×	1.2×	—	—
Dividend payout	0.0%	22.2%	231.1%	−328.3%	1,041.7%	−5,887.2%	—	—

Margins, returns, leverage and liquidityUpdated 31 Dec 2025 ·

ⓘ

Current snapshot ratios have no reporting date and are shown separately from fiscal periods.